How does sharewise work?
Discuss
Discuss and share predictions for your favorite stocks in the forum. Let your opinion be heard
Show moreTop Buy/Sell (This Month)
| Security | Price | Target price |
|---|---|---|
| Micron Technology Inc. | €857.70 | €1,297.5 |
| Delta Air Lines Inc. | €76.55 | €73.39 |
| Aerovironment | €126.70 | €257.49 |
| Security | Price | Target price |
|---|---|---|
| Lennar Corp. A | €73.82 | €73.19 |
| Jetblue Airways Corp. | €5.02 | €3.44 |
| Factset Research Systems | €216.40 | €187.60 |
New Top predictions since last week
| Prediction | User | Perf. (%) |
|---|---|---|
| B Verastem Inc. | michaelkr | 26.33% |
| B Quantumcore Ltd. | AlexanderDanielSchneider | 19.32% |
| B Ichor Holdings Ltd | Zacks Research | 18.03% |
| Prediction | User | Perf. (%) |
|---|---|---|
| S Battalion Oil Corp. | Vassago1 | -23.33% |
| S Veganz Group AG | Wolf_of_WS | -16.32% |
| S Moderna Inc. | Bank of America Co. | -14.19% |
Many tell you which stocks to buy.
We measure how often they are right!
Portfolios of our members
A.D.S.....9
When it comes to stocks, what is important for you?
Find stocks based on your criteria with our sharewise stock finder. All results are based on thousands of votes by our community
Pros and Cons of these stocks (New Predictions)
AI/ML Innovations Inc.
WKN: A2QMBE / Name: AI/ML Innovations / Stock / Micro Cap /
Pros
Cons
Regenxbio Inc
WKN: A140E0 / Name: Regenxbio / Stock / Biotechnology & Medical Research / Small Cap /
Pros
Cons
Try sharewise+ and get hundreds more matching stocks
Sign up for free!Tops & Flops S&P 500
| Security | Price | Change(%) (%) |
|---|---|---|
| Whirlpool Corp. | €35.67 | 7.180% |
| Meta Platforms Inc. | €586.30 | 5.990% |
| Discovery Communications C | €22.42 | 5.110% |
| Clorox Co. | €84.58 | 5.010% |
| Coty Inc | €1.96 | 4.810% |
| Security | Price | Change(%) (%) |
|---|---|---|
| Gilead Sciences Inc | €113.74 | -3.640% |
| A.O. Smith Corp. | €52.96 | -3.540% |
| Delta Air Lines Inc. | €76.55 | -3.290% |
| United Continental Holdings | €110.50 | -3.100% |
| Kansas City Southern | €256.50 | -2.950% |
Courses
sharewise Introduction
sharewise advanced features
Also you get more information about our Pro and Cons feature, where we bring the wisdom of crowds to a new level.
For discussing with your friends and managing your investment clubs we will show you how to create your own stock debates.#
Predictions
Rigetti Computing Inc.
11:35
12.07.27
10.07.26
Steyr Motors AG
11:35
12.07.27
10.07.26
Top News
3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
Key Points
- Interested in VanEck Rare Earth and Strategic Metals ETF? Here are five stocks we like better.
- China's rare-earth dominance stems from decades of investment in refining and processing
Dycom Industries Says Fiber, Data Center Demand Gives Backlog ‘Staying Power’
Key Points
- Interested in Dycom Industries, Inc.? Here are five stocks we like better.
- Dycom sees lasting demand from fiber, long-haul networks and data center projects, with CEO Dan Peyovich
Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
Key Points
- Interested in Microsoft Corporation? Here are five stocks we like better.
- Microsoft is routing some Excel and Outlook prompts to its own MAI models instead of OpenAI or Anthropic to
Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
Key Points
- Interested in Delta Air Lines, Inc.? Here are five stocks we like better.
- Delta Air Lines reported strong Q2 2026 results with revenue up 30.3% and raised guidance, prompting 27
Why "Big Short" Investor Michael Burry Sees Upside in Beaten-Down Sportbook Stocks
Key Points
- Interested in Flutter Entertainment PLC? Here are five stocks we like better.
- Michael Burry recently bought shares of DraftKings and Flutter Entertainment, betting on a recovery in
Q2 Earnings Season Arrives: Can Results Match Upbeat Expectations?
The Q2 earnings season gets going in earnest this week, with almost 70 companies on deck to report results, including 29 S&P 500 members. The big banks dominate this week’s reporting docket, but we
Why V.F. (VFC) Outpaced the Stock Market Today
In the latest close session, V.F. (VFC) was up +1.45% at $16.77. The stock outpaced the S&P 500's daily gain of 0.42%. Elsewhere, the Dow saw an upswing of 0.29%, while the tech-heavy Nasdaq
Astrazeneca (AZN) Stock Dips While Market Gains: Key Facts
In the latest close session, Astrazeneca (AZN) was down 3.85% at $171.61. This move lagged the S&P 500's daily gain of 0.42%. Elsewhere, the Dow saw an upswing of 0.29%, while the tech-heavy Nasdaq
PagSeguro Digital Ltd. (PAGS) Outpaces Stock Market Gains: What You Should Know
In the latest close session, PagSeguro Digital Ltd. (PAGS) was up +2.78% at $9.25. The stock's performance was ahead of the S&P 500's daily gain of 0.42%. Meanwhile, the Dow experienced a rise of
Onto Innovation (ONTO) Surpasses Market Returns: Some Facts Worth Knowing
In the latest trading session, Onto Innovation (ONTO) closed at $321.44, marking a +1.39% move from the previous day. This move outpaced the S&P 500's daily gain of 0.42%. Elsewhere, the Dow gained
Capri Charts Post-Versace Comeback With Michael Kors Revamp, Jimmy Choo Growth
Key Points
- Interested in Capri Holdings Limited? Here are five stocks we like better.
- Capri is refocusing after selling Versace, with management now concentrating on Michael Kors and Jimmy
News
Clarivate to Sell Life Sciences Unit to Altaris for $600M, Refocus Core Business
Key Points
- Interested in Clarivate PLC? Here are five stocks we like better.
- Clarivate will sell substantially all of its Life Sciences & Healthcare segment to Altaris for $600 million, with
Chewy Annual Meeting: Directors Elected, Deloitte Ratified and Pay Vote Approved
Key Points
- Interested in Chewy? Here are five stocks we like better.
- At Chewy’s 2026 Annual Meeting, shareholders elected all five Class I director nominees to three-year terms ending at the
AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stage
Key Points
- Interested in Astrazeneca Plc? Here are five stocks we like better.
- AstraZeneca updated its 2030 sustainability targets, lowering its Scope 3 emissions goal to a 35% reduction from
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
Key Points
- Interested in Vertex Pharmaceuticals Incorporated? Here are five stocks we like better.
- Vertex Pharmaceuticals agreed to buy Crinetics Pharmaceuticals for $85 per share in cash
Veritone Shareholders Back Share Increase, CEO Awards as Debt Questions Loom
Key Points
- Interested in Veritone, Inc.? Here are five stocks we like better.
- Veritone shareholders approved all six proposals at the 2026 annual meeting, including re-electing two directors
Veritone Maps AI Growth Push as Oracle Partnership Targets Cost Savings
Key Points
- Interested in Veritone, Inc.? Here are five stocks we like better.
- Veritone outlined a broad AI strategy centered on turning unstructured data like video, audio and documents into
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
Key Points
- Interested in Vera Therapeutics, Inc.? Here are five stocks we like better.
- Vera Therapeutics won accelerated FDA approval for TRUTAKNA (atacicept-vymj) to treat adults with primary
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout
Key Points
- Interested in Turn Therapeutics Inc.? Here are five stocks we like better.
- Turn Therapeutics refined the stage two design of its GX-03 phase II eczema trial after an interim
TruBridge Stockholders Approve IKS Merger at Special Meeting
Key Points
- Interested in TruBridge, Inc.? Here are five stocks we like better.
- TruBridge stockholders approved the company’s merger agreement with Inventurus Knowledge Solutions Inc. (IKS)
Contest
Still running
Leeway
Die Analyse-Plattform Leeway untersucht mit KI-unterstützten Algorithmen aussagekräftige Zusammenhänge am Aktienmarkt. Anhand von vielen Millionen Datenpunkten finden die Algorithmen die Kennzahlen und Bewegungen, die nachweisbare Auswirkungen haben und Vorteile schaffen.
Kostenlos ausprobieren
Heibel Ticker
sharewise sagt: Stephan Heibel ist ein langähriger Unterstützer und Autor der Wunschanalyse. Er betreibt meiner Meinung nach einen der besten Börsenbriefe. Es gibt eine kostenlose und eine Premium Variante.
Kostenlos ausprobierensharewise
Du findest das sharewise Projekt spannend und möchtest es unterstützen?
Mit einer
sharewise+-Mitgliedschaft
unterstützt du uns finanziell und bekommst zusätzliche Funktionalitäten freigeschalten.
sharewise
Du findest das sharewise Projekt spannend und möchtest es unterstützen?
Mit einer
sharewise+-Mitgliedschaft
unterstützt du uns finanziell und bekommst zusätzliche Funktionalitäten freigeschalten.